New Drugs for Psoriatic Arthritis

Psoriasis is a condition that arises from a problem with the immune system. This involves an inflammatory process that causes thickening of the skin, resulting in large patches that are often not very easy to treat. It can also affect joints, resulting in psoriatic arthritis. Clinical studies evaluated two new drugs, tofacitinib and guselkumab, for the treatment of psoriatic arthritis.

Two new drugs show potential benefits in psoriatic arthritis
- Psoriatic arthritis is an autoimmune disorder affecting joints in patients with the skin condition, psoriasis
- The affected joints become swollen, stiff ans painful
- Two new drugs, tofacitinib and guselkumab, are being evaluated for the treatment of psoriatic arthritis

New Drugs Show Potential in Benefiting Psoriatic Arthritis Patients

Clinical trials are evaluating two new drugs, tofacitinib and guselkumab, for the treatment of psoriatic arthritis. The results appear promising. Read More

Related Links

RapidSSL

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer

This site complies with the HONcode standard for trustworthy health information:
verify here.

New Drugs for Psoriatic Arthritis

New Drugs Show Potential in Benefiting Psoriatic Arthritis Patients

Related Links

Psoriatic Arthritis

Depression Increases Risk of Psoriatic Arthritis Among Psoriasis Patients

Psoriasis

Follow Us On :